Hypofractionated radiotherapy combined with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor, and thymosin-α1 in advanced metastatic solid tumors: a multicenter Phase II clinical trial
In conclusion, the trends in efficacy observed in our study are promising; however, well-designed protocols are essential to validate these findings.
Authors
- Lansheng Zhang (ORCID: https://orcid.org/0000-0003-2772-3797)
- Juying Liu
- Dan Zong
- Wenjie Guo (ORCID: https://orcid.org/0000-0001-8506-3905)
- Yanguang Yang (ORCID: https://orcid.org/0000-0002-6632-2251)
- Hong Jiang (ORCID: https://orcid.org/0000-0003-2812-4120)
- Jiamin Yu (ORCID: https://orcid.org/0000-0002-8989-3997)
- Hongxun Ye
- Xiayun He (ORCID: https://orcid.org/0000-0002-1652-3012)
- Lijun Wang (ORCID: https://orcid.org/0000-0001-9782-6869)
- Qiang Wang (ORCID: https://orcid.org/0000-0002-6141-0068)
- Li Yin (ORCID: https://orcid.org/0000-0003-1951-1487)
- Youyou Xia (ORCID: https://orcid.org/0000-0001-5237-8791)
- Jianfeng Wu
- Wanwei Wang (ORCID: https://orcid.org/0000-0002-1464-4494)
- Jianhong Xia
Institutions
- Jiangsu University (CN)
- Xuzhou Medical College (CN)
- Huaian First People’s Hospital (CN)
- Xuzhou Cancer Hospital (CN)
- Nantong Tumor Hospital (CN)
- Taixing People's Hospital (CN)
- Second People’s Hospital of Huai’an (CN)
- Jiangsu Cancer Hospital (CN)
- The First People’s Hospital of Lianyungang (CN)
- Xuzhou No.1 People's Hospital (CN)
- Yangzhou University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1007/s00262-024-03934-9
- Citations
- 5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- National Natural Science Foundation of China